SCHEMBL179570

SCHEMBL179570

CON(C)C(=O)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18780480 0.81
SCHEMBL23202631 0.81
SCHEMBL15606714 0.79
SCHEMBL12597840 0.79 FAAH (0.41)
SCHEMBL29183039 0.79 FAAH (0.41)
SCHEMBL13080643 0.79
SCHEMBL19770803 0.79
SCHEMBL8941385 0.79
SCHEMBL16945372 0.79
SCHEMBL3151556 0.79 FAAH (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486277-B2 CDK inhibitors and their use as pharmaceuticals Prelude Therapeutis Incorporated (US) 2025-12-02 US disclosed
EP-4650347-A1 PHENYL-SUBSTITUTED HETEROARYL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Meiyue Biotech Development Co., Ltd. (CN) 2025-11-19 EP disclosed
US-12473295-B2 Substituted straight chain spiro derivatives JANSSEN PHARMACEUTICA NV (BE) 2025-11-18 US disclosed
US-20250333421-A1 PYRIDAZINES OR 1,2,4-TRIAZINES SUBSTITUTED BY SPIROCYCLIC AMINES JANSSEN PHARMACEUTICA NV (BE) 2025-10-30 US disclosed
WO-2025224759-A1 INDANOL SUBSTITUTED DIAMINO PYRIMIDINE CARBOXAMIDES AS DUAL ATM/DNA-PK INHIBITORS BUGWORKS RESEARCH INDIA PVT. LTD (IN) 2025-10-30 WO disclosed
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS LLC (US) 2025-10-23 US disclosed
US-12435068-B2 Anthelmintic compounds ELANCO ANIMAL HEALTH GMBH (DE) 2025-10-07 US disclosed
US-20250289801-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-09-18 US disclosed
US-12312359-B2 Inhibitors of the menin-MLL interaction VITAE PHARMACEUTICALS, LLC (US) 2025-05-27 US disclosed
CN-115135642-B Inhibitors of EGFR mutant forms 缆图药品公司 2025-03-04 CN disclosed
US-20060052380-A1 Thieno [2,3,-d]pyridazin-4(5H)-ones; modulation of autoimmune diseases with T-cell antiproliferatives; antiinflammatory; organ transplant rejection; AIDS; chronic obstructive pulmonary disease (COPD); asthma ASTRAZENECA AB (SE) 2006-03-09 US disclosed
WO-2006018735-A2 TRIAZOLOPYRIDINE COMPOUNDS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-02-23 WO disclosed
WO-2006018727-A2 TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION PHARMACIA & UPJOHN COMPANY LLC (US) 2006-02-23 WO disclosed
EP-1587809-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2005-10-26 EP disclosed
US-6852726-B2 Substituted indoles as alpha-1 agonists SYNTEX LLC (US) 2005-02-08 US disclosed
EP-1501826-A2 SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS F. Hoffman-la Roche AG (CH) 2005-02-02 EP disclosed
WO-2004065393-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2004-08-05 WO disclosed
US-20030220319-A1 Substituted indoles as alpha-1 agonists SYNTEX (U.S.A.) LLC 2003-11-27 US disclosed
WO-2003064387-A2 SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS F. HOFFMAN-LA ROCHE AG (CH) 2003-08-07 WO disclosed
WO-1993014086-A1 SUBSTITUTED 1-ISOQUINOLONE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS SYNTEX (U.S.A.) INC. (US) 1993-07-22 WO disclosed